Skip to main content
TipRanks
Go Ultimate75% OFF

Cadrenal Therapeutics, Inc. (CVKD) Ratios

450 Followers

Cadrenal Therapeutics, Inc. Ratios

CVKD's free cash flow for Q2 2026 was $-2.23M. For the 2026 fiscal year, CVKD's free cash flow was increased by $0.00 and operating cash flow was $-2.23M. See a summary of the company’s cash flow.

Financial ratios
RatiosMar 26Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio2.723.7710.270.55
Quick Ratio2.723.7710.270.55
Cash Ratio2.523.7310.160.02
Solvency Ratio-8.33-3.97-10.10-1.06
Operating Cash Flow Ratio-7.94-2.74-4.27-0.90
Short-Term Operating Cash Flow Coverage0.000.000.00-27.55
Net Current Asset Value$ 2.73M$ 7.43M$ 7.67M$ -5.60M
Leverage Ratios
Debt-to-Assets Ratio0.000.000.000.82
Debt-to-Equity Ratio0.000.000.00-0.12
Debt-to-Capital Ratio0.000.000.00-0.13
Long-Term Debt-to-Capital Ratio0.000.000.00-0.11
Financial Leverage Ratio1.581.361.11-0.14
Debt Service Coverage Ratio0.000.00-487.57-43.80
Interest Coverage Ratio0.000.00-446.34-25.22
Debt to Market Cap0.000.000.000.01
Interest Debt Per Share0.000.000.040.96
Net Debt to EBITDA0.300.941.01-0.09
Profitability Margins
Gross Profit Margin0.00%0.00%0.00%0.00%
EBIT Margin0.00%0.00%0.00%0.00%
EBITDA Margin0.00%0.00%0.00%0.00%
Operating Profit Margin0.00%0.00%0.00%0.00%
Pretax Profit Margin0.00%0.00%0.00%0.00%
Net Profit Margin0.00%0.00%0.00%0.00%
Continuous Operations Profit Margin0.00%0.00%0.00%0.00%
Net Income Per EBT100.00%100.00%100.00%100.00%
EBT Per EBIT98.34%97.18%109.49%248.53%
Return on Assets (ROA)-305.95%-105.21%-98.10%-862.83%
Return on Equity (ROE)-483.34%-143.17%-108.64%120.95%
Return on Capital Employed (ROCE)-491.51%-147.33%-99.23%485.64%
Return on Invested Capital (ROIC)-491.51%-147.33%-98.95%551.03%
Return on Tangible Assets-305.95%-105.21%-98.10%-862.83%
Earnings Yield-97.93%-60.28%-86.72%-14.01%
Efficiency Ratios
Receivables Turnover0.000.000.000.00
Payables Turnover0.000.000.000.00
Inventory Turnover0.000.000.000.00
Fixed Asset Turnover0.000.000.000.00
Asset Turnover0.000.000.000.00
Working Capital Turnover Ratio0.000.000.000.00
Cash Conversion Cycle0.000.000.00-116735.71
Days of Sales Outstanding0.000.000.000.00
Days of Inventory Outstanding0.000.000.000.00
Days of Payables Outstanding0.000.000.00116735.71
Operating Cycle0.000.000.000.00
Cash Flow Ratios
Operating Cash Flow Per Share-6.32-6.03-4.07-1.55
Free Cash Flow Per Share-6.32-6.04-4.07-1.55
Dividend Paid and CapEx Coverage Ratio-2468.98-1125.52-1084.920.00
Capital Expenditure Coverage Ratio-2468.98-1125.52-1084.920.00
Operating Cash Flow Coverage Ratio0.000.00-165.35-1.88
Operating Cash Flow to Sales Ratio0.000.000.000.00
Free Cash Flow Yield-93.22%-41.67%-36.67%-2.51%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-1.02-1.66-1.15-7.14
Price-to-Sales (P/S) Ratio0.000.000.000.00
Price-to-Book (P/B) Ratio4.942.381.25-8.64
Price-to-Free Cash Flow (P/FCF) Ratio-1.07-2.40-2.73-39.79
Price-to-Operating Cash Flow Ratio-1.07-2.40-2.73-39.79
Price-to-Earnings Growth (PEG) Ratio0.040.18-0.100.00
Enterprise Value Multiple-0.72-0.72-0.15-7.35
Enterprise Value9.51M7.65M1.26M48.54M
EV to EBITDA-0.72-0.72-0.15-7.35
EV to Sales0.000.000.000.00
EV to Free Cash Flow-0.75-1.04-0.36-40.29
EV to Operating Cash Flow-0.75-1.04-0.36-40.29
Tangible Book Value Per Share1.376.108.86-7.16
Shareholders’ Equity Per Share1.376.108.86-7.16
Tax and Other Ratios
Effective Tax Rate0.000.000.000.00
Revenue Per Share0.000.000.000.00
Net Income Per Share-6.64-8.73-9.63-8.66
Tax Burden1.001.001.001.00
Interest Burden1.001.001.001.02
Research & Development to Revenue0.000.000.000.00
SG&A to Revenue0.000.000.000.00
Stock-Based Compensation to Revenue0.000.000.000.00
Income Quality0.950.690.420.18

Currency in USD